ライフサイエンスコーパス: topical corticosteroid

1 patients because of self-discontinuation of topical corticosteroid.

2 early, but not late, application of a potent topical corticosteroid.

3 and in 44 of 194 (22.7%) first prescribed a topical corticosteroid.

4 of cataract development among eyes receiving topical corticosteroids.

5 ive retreatment achieved using rituximab and topical corticosteroids.

6 abetic and diabetic patients, as compared to topical corticosteroids.

7 ive exclusion of food triggers and swallowed topical corticosteroids.

8 nd subsequent mild uveitis was responsive to topical corticosteroids.

9 hese adverse effects are easily managed with topical corticosteroids.

10 rm, resistant to systemic antihistamines and topical corticosteroids.

11 y retinal lesions and exhibit no response to topical corticosteroids.

12 n eliminating exposure to food allergens, or topical corticosteroids.

13 e assessed with attention paid to the use of topical corticosteroids.

14 eive dupilumab (n=83) or placebo (n=79) plus topical corticosteroids.

15 0 mg were well tolerated in combination with topical corticosteroids.

16 f Dermatology, and an inadequate response to topical corticosteroids.

17 tors (PPIs), food elimination diet (FED), or topical corticosteroids.

18 colitis, starting with topical mesalamine or topical corticosteroids.

19 from repeated use of systemic treatments or topical corticosteroids.

20 The most common treatments were systemic and topical corticosteroids.

21 r disease with basic skin care practices and topical corticosteroids.

22 well tolerated and superior to placebo plus topical corticosteroids.

23 s than in patients treated with placebo plus topical corticosteroids.

24 e response associated with keratitis include topical corticosteroids.

25 oton pump inhibitors, elimination diets, and topical corticosteroids.

26 At baseline, 56 eyes (75%) were on topical corticosteroids.

27 cal corticosteroids, and 315 to placebo plus topical corticosteroids.

28 calcineurin inhibitors where inadvisable for topical corticosteroids.

29 hritis (JIA)-associated uveitis treated with topical corticosteroids.

30 in this series had an inadequate response to topical corticosteroids.

31 ipants said that they need reassurance about topical corticosteroids.

32 o steroid group) resolved with resumption of topical corticosteroids.

33 lar GVHD without the hypertensive effects of topical corticosteroids.

34 o assess patients' worries and beliefs about topical corticosteroids.

35 ts were treated with aggressive systemic and topical corticosteroids.

36 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topic

37 of cataract, especially time-updated use of topical corticosteroids 2 times/d or 4 periocular cortic

38 Treatments included topical corticosteroids (277 [81.5%], either alone or in

39 ralesional corticosteroids (370 [37.3%]) and topical corticosteroids (342 [34.5%]), followed by doxyc

40 he most common treatments during flares were topical corticosteroids (35% of episodes [178 of 513]),

41 tments were proton pump inhibitors (83%) and topical corticosteroids (51%).

42 ng the 60 497 matched pregnancies exposed to topical corticosteroids, 5678 (9.4%) of the delivered in

43 Es that were treated, most were treated with topical corticosteroids (75.5%), 28.3% by systemic corti

44 5 [44.1%], P < .001) and higher frequency of topical corticosteroid (817 [25.4%] vs 17 787 [42.1%], P

45 83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received

46 were removed from the study and treated with topical corticosteroids according to best medical judgme

47 6, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints

48 rneal erosions, such as oral doxycycline and topical corticosteroid, alcohol delamination, substance

49 Use of superpotent topical corticosteroids alone (by 100 patients [83.3%])

50 ainst BP230 confirmed the use of superpotent topical corticosteroids alone as a reference BP treatmen

51 oderate (8.8%) intensity; most resolved with topical corticosteroids alone.

52 Adjunctive topical corticosteroids also did not improve scar size a

53 n of the suspected agent in conjunction with topical corticosteroid and cycloplegic therapy.

54 ve patients were treated preoperatively with topical corticosteroids and anti-CMV treatment (oral val

55 Topical corticosteroids and calcineurin inhibitors are a

56 Topical corticosteroids and calcineurin inhibitors are w

57 inhibitors; new topical combinations such as topical corticosteroids and calcipotriene; and new techn

58 ing adalimumab therapy since they respond to topical corticosteroids and do not necessarily prompt th

59 A combination of topical corticosteroids and NSAIDs significantly reduced

60 udy (HEDS) I showed a significant benefit of topical corticosteroids and oral acyclovir for stromal k

61 tment regimen that includes a combination of topical corticosteroids and topical cidofovir as a desir

62 g atopic dermatitis (AD) was still primarily topical corticosteroids and, for more severe disease, sy

63 Adjunctive topical corticosteroids and/or corneal cross-linking (CX

64 drugs, but severe cases need treatment with topical corticosteroids and/or immunotherapy (SCIT).

65 Thirty-seven cases (66%) were treated with topical corticosteroids and/or observation alone.

66 Articles on topical corticosteroids and/or topical calcineurin inhib

67 rator controls, and 1 067 280 controls using topical corticosteroids) and 3 unique case-control studi

68 patients (41.5%) filled a prescription for a topical corticosteroid, and 1087 patients (9.4%) receive

69 (31.7%), respectively, made comparisons with topical corticosteroids, and 25 (64.1%) and 15 (36.6%),

70 l corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical

71 arious treatments, including UV irradiation, topical corticosteroids, and a Jak inhibitor, were teste

72 on subtype; anterior uveitis is treated with topical corticosteroids, and mild intermediate uveitis m

73 Eighteen patients were treated with topical corticosteroids, and only 1 patient required dis

74 The patient was treated with topical corticosteroids, and six months later, there was

75 nt received a combination of antihistamines, topical corticosteroids, and thick emollient creams, ren

76 s the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibi

77 nd anterior uveitis were managed with mainly topical corticosteroids, antibiotics, lubricants, and sy

78 Of note, superpotent topical corticosteroid application quickly and markedly

79 Topical corticosteroids are first-line agents to manage

80 Topical corticosteroids are frequently used during pregn

81 Topical corticosteroids are indicated for pregnant women

82 For severe chronic hand eczema, topical corticosteroids are often unsatisfactory and sys

83 Topical corticosteroids are the current first-line thera

84 Long-term topical corticosteroids are unnecessary following PRK wi

85 when large amounts of potent to very potent topical corticosteroids are used in pregnancy.

86 ilable treatments of NIU, such as the use of topical corticosteroids, are non-specific and have serio

87 Patients treated with topical corticosteroids as adjunctive therapy within 2 t

88 eatment received rituximab with high-potency topical corticosteroids as first-line treatment.

89 The use of topical corticosteroids as local therapy for anterior uv

90 week, as monotherapy or in combination with topical corticosteroids as needed, provides significant

91 2 [monotherapy] and ECZTRA 3 [tralokinumab + topical corticosteroids as needed]).

92 Exposure to potent to very potent topical corticosteroids at any amount was not associated

93 terior synechiae, active uveitis, and use of topical corticosteroids at presentation were significant

94 The outcomes of patients treated with topical corticosteroids before diagnosis of AK were comp

95 AK were compared with those not treated with topical corticosteroids before diagnosis.

96 inystalia yohimbe); potentiation of oral and topical corticosteroids by liquorice (Glycyrrhiza glabra

97 nonactive (RR, 1.86; 95% CI, 1.39-2.49) and topical corticosteroid comparators (RR, 1.35; 95% CI, 1.

98 the efficacy and safety of upadacitinib plus topical corticosteroids compared with placebo for the tr

99 ncreased significantly in eyes that received topical corticosteroids (compared to NSAIDs; HR = 5.72,

100 The combination of rituximab and topical corticosteroids could be considered in mild to s

101 Topical corticosteroids could be tapered, stopped, or re

102 czema in 2009 compared to 51.4% in 2018) and topical corticosteroids decreased (57.3%-52.0%).

103 scribing over time; emollients increased and topical corticosteroids decreased (57.3%-52.0%).

104 sing the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endos

105 Topical corticosteroids dispensed during pregnancy.

106 However, chronic use of topical corticosteroids dosed at <3 drops daily seemed t

107 ns (oral prednisone 7.5 mg daily or less, or topical corticosteroid drops <2 times/d) were not associ

108 oral corticosteroids to less than 10 mg/d or topical corticosteroid drops to less than 2 drops daily,

109 Most eyes (95.3%, N = 349) were treated with topical corticosteroid drops, and only 6 (1.6%) received

110 Filled prescriptions for topical corticosteroids during pregnancy.

111 not week 24 because of an increased placebo/topical corticosteroid effect (36.8% vs 21.1%, P = .06).

112 Proton pump inhibitors, swallowed topical corticosteroids, elimination diets, and dupiluma

113 Systemic or topical corticosteroids, elimination diets, proton pump

114 wever, maternal use of potent to very potent topical corticosteroids, especially when the cumulative

115 Continued once-per-day use of a topical corticosteroid, even a weak one, was protective

116 he dispensed amount of potent or very potent topical corticosteroids exceeded 300 g during the entire

117 ies, this nationwide cohort study identified topical corticosteroid-exposed pregnancies in Denmark fr

118 No associations of maternal topical corticosteroid exposure with orofacial cleft, lo

119 ssuringly showed no associations of maternal topical corticosteroid exposure with orofacial cleft, pr

120 ight seems to correlate with the quantity of topical corticosteroid exposure.

121 Topical corticosteroid eye drop is the mainstay for prev

122 aline and the other treated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabo

123 placebo once daily, all in combination with topical corticosteroids for 16 weeks.

124 Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %),

125 opical antifungals for oral candidiasis, and topical corticosteroids for aphthous ulcers.

126 tive effectiveness trials such as the use of topical corticosteroids for pemphigoid may have played a

127 Active comparators (mild topical corticosteroids for pimecrolimus and moderate to

128 oids for pimecrolimus and moderate to potent topical corticosteroids for tacrolimus) are best placed

129 the risk benefit associated with the use of topical corticosteroids for the management of inflammato

130 stemic therapies are typically combined with topical corticosteroids for the management of moderate-t

131 Her findings resolved with observation and topical corticosteroids for uveitis.

132 rgery when compared directly with placebo or topical corticosteroid formulations with limited intraoc

133 cantly higher in the upadacitinib 15 mg plus topical corticosteroid group (119 [40%] patients) and up

134 [40%] patients) and upadacitinib 30 mg plus topical corticosteroid group (174 [59%] patients) than t

135 cantly higher in the upadacitinib 15 mg plus topical corticosteroid group (194 [65%] of 300 patients)

136 00 patients) and the upadacitinib 30 mg plus topical corticosteroids group (229 [77%] of 297 patients

137 and seven [2%] patients in the placebo plus topical corticosteroids group) and serious adverse event

138 [1%] patients in the upadacitinib 30 mg plus topical corticosteroids group, and seven [2%] patients i

139 [1%] patients in the upadacitinib 15 mg plus topical corticosteroids group, four [1%] patients in the

140 anterior chamber cells of >/=1+ or requiring topical corticosteroid >/=3 times daily, and who were on

141 To date, therapy with topical corticosteroids has been shown to reverse esopha

142 0 kg: 300 mg) every 4 weeks plus low-potency topical corticosteroids (hydrocortisone acetate 1% cream

143 iving large amounts of potent to very potent topical corticosteroids (ie, >200 g throughout pregnancy

144 There may be a benefit with adjunctive topical corticosteroids if application occurs earlier in

145 excisional biopsy in 5 patients (5/9, 56%), topical corticosteroids in 2 patients (2/9, 22%), and ob

146 njections every 4 weeks versus placebo, with topical corticosteroids in adults with moderate-to-sever

147 topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-sever

148 ty of dupilumab with concomitant low-potency topical corticosteroids in children aged 6 months to you

149 Compared with a wide potency range of topical corticosteroids in clinical formulations, 0.3% a

150 Although our results using topical corticosteroids in mice are highly promising for

151 g less prescribing of potent and very potent topical corticosteroids in non-white ethnicities and peo

152 ed the odds of developing CME as compared to topical corticosteroids in nondiabetic (odds ratio [OR]

153 ed the odds of developing CME as compared to topical corticosteroids in nondiabetic (OR 0.21; 95% CI

154 Long-term use of topical corticosteroids in skin inflammation poses risks

155 is of herpes keratitis and before the use of topical corticosteroids in the therapy of any indolent k

156 d the odds of developing CME, as compared to topical corticosteroids, in nondiabetic and mixed popula

157 ions increased a mean of 195%, and prices of topical corticosteroids increased a mean of 290% during

158 On multivariable analysis, topical corticosteroids increased the odds of PCR-positi

159 e evaluated whether treatment with swallowed topical corticosteroids is able to reduce the risk of oc

160 studies have shown that medical therapy with topical corticosteroids is effective in treating EoE, th

161 ion, even using higher doses of systemic and topical corticosteroids, is of importance in preventing

162 Localised adjuvant potent topical corticosteroids (<30 g per week) were permitted

163 uals with allergic contact dermatitis to one topical corticosteroid may also react to other corticost

164 Participants were required to apply topical corticosteroids (medium or low potency), topical

165 ren, because conventional treatments such as topical corticosteroids might be inadequate or cause con

166 h comparisons with active treatments such as topical corticosteroids might have been included or avoi

167 elemental diet, 6-food elimination diet, or topical corticosteroids (n = 6 per group).

168 icosteroids (n=300), upadacitinib 30 mg plus topical corticosteroids (n=297), or placebo plus topical

169 assigned to receive upadacitinib 15 mg plus topical corticosteroids (n=300), upadacitinib 30 mg plus

170 cal corticosteroids (n=297), or placebo plus topical corticosteroids (n=304).

171 ich was mostly mild and well controlled with topical corticosteroids, occurred in 70.7% of lenadogene

172 nce found no associations of maternal use of topical corticosteroids of any potency with mode of deli

173 ce for anogenital lichen sclerosus is potent topical corticosteroid ointment for a limited time.

174 Topical corticosteroids only were associated with increa

175 Treatment with potent topical corticosteroids or methotrexate sodium led to re

176 s by using proactive approaches (with either topical corticosteroids or topical calcineurin inhibitor

177 12% [39 patients] who received placebo plus topical corticosteroids; p<0.0001) and EASI-75 (64% [204

178 More than half of the participants believed topical corticosteroids pass into bloodstream, damage th

179 on to endophthalmitis include patients using topical corticosteroids, patients with fungal keratitis,

180 volves skin directed therapies which include topical corticosteroids, phototherapy (psoralen with UVA

181 ed grade 2/3 pruritus that was refractory to topical corticosteroids plus at least one additional sys

182 Topical corticosteroid potency classifications were assi

183 l cases were treated with intensive, potent, topical corticosteroids: prednisolone acetate 1% eye dro

184 Topical corticosteroids, preferably those with reduced s

185 % [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who rec

186 The topical corticosteroid regimen used in this study was si

187 Are topical corticosteroids safe for use in pregnancy?

188 ect the treatment of isolated keratitis, (2) topical corticosteroids should not be used for treating

189 Treatment of EoE with swallowed topical corticosteroids significantly reduces the risk f

190 hing and burning skin and preferred to apply topical corticosteroids sparingly.

191 Swallowed topical corticosteroids (STC) belong to the therapeutic

192 w treatment options; EoE can be treated with topical corticosteroids, such as fluticasone and budeson

193 Approaches to management of MAR include topical corticosteroids, systemic corticosteroids, and/o

194 atments for cirAEs included a combination of topical corticosteroids, systemic corticosteroids, stero

195 e 70 AEs, 61 (87.1%) were treated, most with topical corticosteroids; systemic and intraocular cortic

196 Topical corticosteroid (TCS) phobia refers to the negati

197 We assessed the impact of a standard topical corticosteroid (TCS) treatment, triamcinolone ac

198 We classified topical corticosteroids (TCS) using 7 groups-group 1 bei

199 g placebo once every 4 weeks with background topical corticosteroids (TCS) with or without topical ca

200 gnoses up to 3 years, including frequency of topical corticosteroid-(TCS) use and food intake status.

201 Topical corticosteroids (TCSs) are available in multiple

202 oporotic fracture (MOF) after application of topical corticosteroids (TCSs) is largely unexplored.

203 from children (n = 32) with EoE treated with topical corticosteroids (TCSs) over 10 years (mean, 4.5

204 y associated with bolus impaction: swallowed topical corticosteroid therapy (OR 0.411, 95%-CI 0.203-0

205 iate logistic regression modeling: swallowed topical corticosteroid therapy (OR 0.503, 95%-CI 0.255-0

206 I can be a safe and effective alternative to topical corticosteroid therapy after cataract surgery.

207 rts daily high-volume saline irrigation with topical corticosteroid therapy as a first-line therapy f

208 The second case outlines the use of topical corticosteroid therapy as an adjunct to non-surg

209 Topical corticosteroid therapy improved overall symptom

210 Adjunctive topical corticosteroid therapy may be associated with im

211 Treatment with elimination diets and/or topical corticosteroid therapy slow disease progression,

212 art of AAT and subsequently at the time that topical corticosteroid therapy was initiated.

213 Intensified topical corticosteroid therapy was started immediately a

214 Symptoms and infiltrates regressed after topical corticosteroid therapy, but recurred after each

215 s reassurance that the potential benefits of topical corticosteroid therapy, for treating pain and di

216 Of the 60 eyes in 40 patients who received topical corticosteroid therapy, there was a dose-depende

217 flammation (n = 1), which resolved following topical corticosteroid therapy.

218 erved in all patients, and none responded to topical corticosteroid therapy.

219 The patient was successfully treated using topical corticosteroid therapy.

220 grade II dermatitis that was unresponsive to topical corticosteroid therapy.

221 Despite prompt treatment with topical corticosteroids, these 3 patients eventually req

222 ds, especially when the cumulative dosage of topical corticosteroids throughout the pregnancy is very

223 of participants were anxious about applying topical corticosteroids to certain zones like eyelids, a

224 hoose whether to stop or continue once-daily topical corticosteroids to maximize compliance.

225 We further determined the impact of topical corticosteroids to reactivate Borrelia locally i

226 trial that overall found no effect of adding topical corticosteroids to topical moxifloxacin hydrochl

227 ctored thermal pulsation therapy (Lipiflow), topical corticosteroids, topical cyclosporine A, topical

228 Medical interventions included topical corticosteroids, topical cyclosporine, topical v

229 mmon in patients treated with dupilumab plus topical corticosteroids-treated patients than in patient

230 aHR, 4.14; 95% CI,1.28-13.4, respectively), topical corticosteroid treatment (aHR, 2.84; 95% CI, 1.3

231 INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved ato

232 led trial assessing the effect of adjunctive topical corticosteroid treatment on outcomes in bacteria

233 After 8 days of topical corticosteroid treatment visual acuity was worse

234 The mean duration of topical corticosteroid treatment was 45 +/- 28 days (med

235 i-Programmed cells Death-1 was stopped and a topical corticosteroid treatment was administrated.

236 randomized trials of 437 patients with EoE, topical corticosteroid treatment was associated with his

237 After topical corticosteroid treatment, the inflammation resol

238 using Huber robust regression, adjusting for topical corticosteroid treatment.

239 for a total of 6 doses in addition to daily topical corticosteroid treatment.

240 mized trial to compare nebulized and viscous topical corticosteroid treatments for eosinophilic esoph

241 al graft (20.6% vs 0%, P = .0012), and prior topical corticosteroid use (23.5% vs 5%, P = .019).

242 ncluded a history of ocular surgery (62.5%), topical corticosteroid use (35.4%), and dry eye syndrome

243 esenting visual acuity worse than 20/40, and topical corticosteroid use (in a dose-response relations

244 tio [HR] 2.86, 95% CI 1.52, 5.42; P = .001), topical corticosteroid use (time-updated HR 3.13, 95% CI

245 ds in the last 3 months (aHR, 2.23); current topical corticosteroid use [>/=8x/day vs. none] (aHR, 2.

246 chamber paracentesis and association between topical corticosteroid use and viral load at time of pos

247 ficantly associated with worse outcomes were topical corticosteroid use before the start of AAT (OR,

248 Topical corticosteroid use could often be reduced or sto

249 ge cohort study found no association between topical corticosteroid use in pregnancy and an increased

250 While the frequent topical corticosteroid use is associated with risk of in

251 In our cohort, topical corticosteroid use was associated with an increa

252 Increasing frequency of topical corticosteroid use was significantly associated

253 , sex, prior oral corticosteroid dose, prior topical corticosteroid use, and concomitant immunosuppre

254 Poor ocular surface, topical corticosteroid use, previous ocular surgery, and

255 oral proximity to diagnosis of arthritis and topical corticosteroid use.

256 and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cort

257 the mainstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineuri

258 -B, when used in combination with psoralens, topical corticosteroids, vitamin D analogues, fluorourac

259 41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who receive

260 We assess the effect of topical corticosteroids (vs placebo) on 3-month best spe

261 ed fashion, treatment with <3 drops daily of topical corticosteroid was associated with an 87% lower

262 Use of topical corticosteroids was associated with cataract for

263 oxifloxacin alone, adjunctive treatment with topical corticosteroids was associated with significantl

264 overall patch test positivity for allergy to topical corticosteroids was rare.

265 Upadacitinib plus topical corticosteroids was well tolerated and superior

266 In the youngest 2 groups, topical corticosteroids were also applied.

267 tified in which pimecrolimus, tacrolimus, or topical corticosteroids were compared with another inter

268 atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals,

269 scleritis and hypopyon at the start of AAT, topical corticosteroids were not associated with worse o

270 Treatments with systemic and topical corticosteroids were not significant risk factor

271 omized clinical trial reveal that adjunctive topical corticosteroids were not superior to placebo, an

272 Additionally, topical corticosteroids were prescribed in 18 eyes and t

273 Oral prednisone and topical corticosteroids were tapered.

274 Current clinical treatments use topical corticosteroids, which broadly and transiently s

275 nts with recurrent nasal polyposis receiving topical corticosteroids who required surgery, mepolizuma

276 r disease limited to the nails, high-potency topical corticosteroids with or without calcipotriol are

277 All three groups were given concomitant topical corticosteroids with or without topical calcineu

278 Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atro

279 ll patients had been treated previously with topical corticosteroids without any improvement and also